Literature DB >> 1459192

Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure in rats.

N Mino1, M Kobayashi, A Nakajima, H Amano, K Shimamoto, K Ishikawa, K Watanabe, M Nishikibe, M Yano, F Ikemoto.   

Abstract

To elucidate the pathophysiological role of endogenous endothelin (ET), we examined the effects of the newly synthesized ETA receptor-selective antagonist, BQ-123, on ischemic acute renal failure induced by bilateral clamping of renal artery and vein followed by reperfusion in rats. BQ-123, when given by i.v. infusion of 0.5 mg/kg per min for 2.5 h during the pre- and post-ischemic period, was found to prevent the decrease in creatinine clearance and increases in blood urea nitrogen, plasma creatinine and the fractional excretion of sodium. Morphological observation also showed an effect of BQ-123, i.e. prevention of proximal tubular (S3 segment) necrosis. At 2 h after the start of reperfusion, the ET-1 content in the kidney increased to its maximal level. At this time, the Ca2+ content in the mitochondrial fraction of the renal cortex increased, with a concomitant increase in blood urea nitrogen. However, these increases were limited by treatment with BQ-123. Thus, BQ-123 was effective to both prevent mitochondrial Ca2+ accumulation in the early phase of ischemic acute renal failure and protect proximal tubular cells from post-ischemic degeneration. We conclude that ET may be at least partially involved in the pathogenesis of tubular cell injury in this acute renal failure model.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1459192     DOI: 10.1016/0014-2999(92)90774-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  15 in total

1.  [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature.

Authors:  A P Davenport; R E Kuc; S L Hoskins; F E Karet; F Fitzgerald
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

2.  Endothelin mediated nitric oxide effects in ischemia--reperfusion associated with pancreas transplantation.

Authors:  G Hotter; F Pi; C Sanz; C Peralta; N Prats; E Gelpi; F Badosa; L Fernández-Cruz; J Roselló-Catafau
Journal:  Dig Dis Sci       Date:  1998-12       Impact factor: 3.199

Review 3.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 4.  Endothelin in cardiovascular control: the role of endothelin antagonists.

Authors:  R R Wenzel; P Czyborra; T Lüscher; T Philipp
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

5.  Down regulation of kidney neutral endopeptidase mRNA, protein and activity during acute renal failure: possible mechanism for ischemia-induced acute renal failure in rats?

Authors:  P Nambi; M Pullen; H L Wu; U Prabhakar; L Hersh; M Gellai
Journal:  Mol Cell Biochem       Date:  1999-07       Impact factor: 3.396

6.  Protective effects of endothelin-1 on acute pancreatitis in rats.

Authors:  M Kogire; K Inoue; S Higashide; K Takaori; Y Echigo; Y J Gu; S Sumi; K Uchida; M Imamura
Journal:  Dig Dis Sci       Date:  1995-06       Impact factor: 3.199

7.  ETA receptor-mediated responses to endothelin-1 and big endothelin-1 in the rat kidney.

Authors:  D M Pollock; T J Opgenorth
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

8.  Reversal of postischemic acute renal failure with a selective endothelinA receptor antagonist in the rat.

Authors:  M Gellai; M Jugus; T Fletcher; R DeWolf; P Nambi
Journal:  J Clin Invest       Date:  1994-02       Impact factor: 14.808

Review 9.  Endothelin and endothelin antagonists: potential role in cardiovascular and renal disease.

Authors:  G Noll; R R Wenzel; T F Lüscher
Journal:  Mol Cell Biochem       Date:  1996 Apr 12-26       Impact factor: 3.396

10.  Pharmacology of a non-selective ETA and ETB receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats.

Authors:  T Watanabe; Y Awane; S Ikeda; S Fujiwara; K Kubo; T Kikuchi; K Kusumoto; M Wakimasu; M Fujino
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.